Antipsychotics update
January 19, 2012
THIS year’s PSA Offshore
Refresher Conference will feature a
presentation on antipsychotics,
including some rules to help
understand the differences and
similarities of the conventional and
atypical antipsychotics.
The lecture will be presented by
Professor Andrew McLachlan,
Education Director of the Refresher
Conference, and will include results
from the CATIE study, which
showed there were no differences
in symptom scores and quality-oflife
measures between most
antipsychotics.
“However there are differences
between safety and tolerability and
have a greater impact on therapy
than any difference in efficacy,” the
PSA said in a statement.
“Because of these substantial
adverse effects, non-adherence is a
common cause of treatment failure
and pharmacists have an important
role in assisting patients cope with
the adverse affects including weight
gain, hyperprolactinaemia, sedation
or activation, anticholinergic effects
plus recognising the symptoms of
orthostatic hypotension and QT
prolongation,” the PSA added.
For info phone 1300 139 293.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jan 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jan 12
